Systemic adverse events in imiquimod use for cervical intraepithelial neoplasia - A case series

Tirza Wouters*, Natasja Hendriks, Margot Koeneman, Arnold-Jan Kruse, Anna van de Sande, Heleen J van Beekhuizen, Kees G Gerestein, Ruud L M Bekkers, Jurgen M J Piek

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Treatment for cervical intraepithelial neoplasia (CIN) often consists of an excisional procedure. However, less invasive treatment methods have been explored, such as topical treatment with imiquimod cream. Imiquimod has been proven to be effective in the regression of vulvar intraepithelial neoplasia (VIN) and vaginal intraepithelial neoplasia (VAIN). Previous studies have investigated the effect of imiquimod in CIN and showed well tolerated adverse effects. During a current study in the Netherlands, a number of adverse events have occurred. This case series presents a selection of these. Gynaecologists should be aware of the possible adverse effects of topical treatment with imiquimod cream.

Original languageEnglish
Article numbere00105
JournalCase Reports in Women's Health
Volume21
DOIs
Publication statusPublished - Jan 2019

Cite this

Wouters, T., Hendriks, N., Koeneman, M., Kruse, A-J., van de Sande, A., van Beekhuizen, H. J., Gerestein, K. G., Bekkers, R. L. M., & Piek, J. M. J. (2019). Systemic adverse events in imiquimod use for cervical intraepithelial neoplasia - A case series. Case Reports in Women's Health, 21, [e00105]. https://doi.org/10.1016/j.crwh.2019.e00105